FLX 925

Drug Profile

FLX 925

Alternative Names: AMG 925; FLX925

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer FLX Bio
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 05 Oct 2017 FLX Bio terminates a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA, as the dose escalation part completed (PO) (NCT02335814)
  • 08 Apr 2015 Flexus Biosciences has been acquired by Bristol-Myers Squibb
  • 01 Jan 2015 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT02335814)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top